This change follows the resignation of Richard Donnelly from his roles as an officer and director of AspenBio. Mr Donnelly has indicated that he plans to pursue other business opportunities, but has agreed to provide transition and consulting services for a period of time. Some of Mr Donnelly’s responsibilities will also be assumed by Robert Caspari, the company’s new COO and chief medical officer.
AspenBio Pharma has also promoted Mark Colgin to a new position of chief scientific officer. He has led the company’s new product development and scientific project management since joining AspenBio in 2000.
Greg Pusey, vice chairman of AspenBio, said: “We continue to achieve important milestones for AspenBio, including the recent addition of board members with significant industry expertise followed by the appointments of highly accomplished members to our executive management team. With today’s addition of Dr Caspari, Mr Faulkner has now assembled an executive team which has more than 100 years’ combined industry related experience.”